Shenzhen YHLO Biotech Co Ltd
SSE:688575
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.01
17.59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Shenzhen YHLO Biotech Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shenzhen YHLO Biotech Co Ltd
SSE:688575
|
8.9B CNY |
8%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
222.2B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
212.5B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
145B USD |
14%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.1B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
128.6B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.7B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.6B USD |
8%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
56.5B USD |
25%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49.9B USD |
23%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
39.5B USD |
11%
|
Shenzhen YHLO Biotech Co Ltd
Glance View
In the bustling city of Shenzhen, a beacon of China's rapid technological advancement, YHLO Biotech Co Ltd has emerged as a dynamic player in the healthcare diagnostics industry. Founded in 2008, YHLO Biotech focuses on the development, manufacturing, and distribution of in-vitro diagnostic products. By leveraging cutting-edge immunodiagnostic technologies, the company spearheads innovations in autoimmune disease diagnostics, infectious disease testing, and respiratory pathogen detection. Driven by a commitment to precision and reliability, YHLO Biotech integrates advanced automation solutions and robust biological research to produce diagnostic kits that serve hospitals, laboratories, and research institutions across the globe. YHLO Biotech's business model revolves around an intricate blend of product sales and strategic partnerships. By establishing a diverse portfolio of diagnostic instruments and reagent kits, they cater to both public and private healthcare sectors. The company also engages in collaborations with international diagnostic companies, enhancing its global footprint and broadening market access. Revenue generation at YHLO Biotech is primarily rooted in the sale of these diagnostic solutions, which are consistently updated to meet evolving medical standards and demands. Coupled with their investment in R&D and a rigorous quality control process, YHLO Biotech not only maintains a competitive edge but also fortifies its position as a trusted entity within the medical diagnostics landscape.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Shenzhen YHLO Biotech Co Ltd's most recent financial statements, the company has Net Margin of 8.3%.